Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 145

1.

Non-infectious granulomatous dermatoses.

Schmitt A, Volz A.

J Dtsch Dermatol Ges. 2019 May;17(5):518-533. doi: 10.1111/ddg.13848.

PMID:
31115996
2.

Nicht-infektiöse granulomatöse Dermatosen.

Schmitt A, Volz A.

J Dtsch Dermatol Ges. 2019 May;17(5):518-535. doi: 10.1111/ddg.13848_g.

PMID:
31115989
3.

Extended surgical safety margins and ulceration are associated with an improved prognosis in pleomorphic dermal sarcomas.

Persa OD, Loquai C, Wobser M, Baltaci M, Dengler S, Kreuter A, Volz A, Laimer M, Emberger M, Doerler M, Mauch C, Helbig D.

J Eur Acad Dermatol Venereol. 2019 Feb 14. doi: 10.1111/jdv.15493. [Epub ahead of print]

PMID:
30767327
4.

Physiologically-Based Pharmacokinetic Models for CYP1A2 Drug-Drug Interaction Prediction: A Modeling Network of Fluvoxamine, Theophylline, Caffeine, Rifampicin, and Midazolam.

Britz H, Hanke N, Volz AK, Spigset O, Schwab M, Eissing T, Wendl T, Frechen S, Lehr T.

CPT Pharmacometrics Syst Pharmacol. 2019 May;8(5):296-307. doi: 10.1002/psp4.12397. Epub 2019 Mar 13.

5.

CD8+ T Cells Responding to the Middle East Respiratory Syndrome Coronavirus Nucleocapsid Protein Delivered by Vaccinia Virus MVA in Mice.

Veit S, Jany S, Fux R, Sutter G, Volz A.

Viruses. 2018 Dec 16;10(12). pii: E718. doi: 10.3390/v10120718.

6.

Bardet-Biedl Syndrome proteins regulate cilia disassembly during tissue maturation.

Patnaik SR, Kretschmer V, Brücker L, Schneider S, Volz AK, Oancea-Castillo LDR, May-Simera HL.

Cell Mol Life Sci. 2019 Feb;76(4):757-775. doi: 10.1007/s00018-018-2966-x. Epub 2018 Nov 16.

PMID:
30446775
7.

Generation of therapeutic antisera for emerging viral infections.

Schmidt R, Beltzig LC, Sawatsky B, Dolnik O, Dietzel E, Krähling V, Volz A, Sutter G, Becker S, von Messling V.

NPJ Vaccines. 2018 Oct 5;3:42. doi: 10.1038/s41541-018-0082-4. eCollection 2018.

8.

A cellulose-based material for vascularized adipose tissue engineering.

Volz AC, Hack L, Kluger PJ.

J Biomed Mater Res B Appl Biomater. 2019 Jul;107(5):1431-1439. doi: 10.1002/jbm.b.34235. Epub 2018 Sep 29.

PMID:
30267635
9.

Immunogenic cell death of dendritic cells following modified vaccinia virus Ankara infection enhances CD8+ T cell proliferation.

Tappe KA, Budida R, Stankov MV, Frenz T, R Shah H, Volz A, Sutter G, Kalinke U, Behrens GMN.

Eur J Immunol. 2018 Dec;48(12):2042-2054. doi: 10.1002/eji.201847632. Epub 2018 Oct 10.

PMID:
30259962
10.

Geschickte Positionierung Burowscher Dreiecke lokaler Lappenplastiken zum ästhetisch ansprechenden Verschluss multipler Defekte nach Tumorexzisionen.

Volz A, Häusermann P.

J Dtsch Dermatol Ges. 2018 Sep;16(9):1166-1169. doi: 10.1111/ddg.13624_g. No abstract available.

PMID:
30179333
11.

Tracking Modified Vaccinia Virus Ankara in the Chicken Embryo: In Vivo Tropism and Pathogenesis of Egg Infections.

Langenmayer MC, Lülf-Averhoff AT, Adam-Neumair S, Sutter G, Volz A.

Viruses. 2018 Aug 24;10(9). pii: E452. doi: 10.3390/v10090452.

12.

Optimal placement of Burow's triangles for aesthetically pleasing repair of multiple defects using local flaps after tumor excision.

Volz A, Häusermann P.

J Dtsch Dermatol Ges. 2018 Sep;16(9):1166-1169. doi: 10.1111/ddg.13624. Epub 2018 Aug 16. No abstract available.

PMID:
30112823
13.

Completely defined co-culture of adipogenic differentiated ASCs and microvascular endothelial cells

Volz AC, Hack L, Atzinger FB, Kluger PJ.

ALTEX. 2018;35(4):464-476. doi: 10.14573/altex.1802191. Epub 2018 Jun 13.

14.

Distribution and absence of generalized lesions in mice following single dose intramuscular inoculation of the vaccine candidate MVA-MERS-S.

Langenmayer MC, Lülf-Averhoff AT, Adam-Neumair S, Fux R, Sutter G, Volz A.

Biologicals. 2018 Jul;54:58-62. doi: 10.1016/j.biologicals.2018.05.004.

PMID:
29759890
15.

Completely serum-free and chemically defined adipocyte development and maintenance.

Volz AC, Kluger PJ.

Cytotherapy. 2018 Apr;20(4):576-588. doi: 10.1016/j.jcyt.2018.01.004. Epub 2018 Mar 1.

PMID:
29496462
16.

"Shark island pedicle flap" zur Defektdeckung der lateralen Ala nasi und Perialarregion.

Volz A, Frauenknecht V, Häusermann P.

J Dtsch Dermatol Ges. 2018 Jan;16(1):108-111. doi: 10.1111/ddg.13397_g. No abstract available.

PMID:
29314672
17.

E3L and F1L Gene Functions Modulate the Protective Capacity of Modified Vaccinia Virus Ankara Immunization in Murine Model of Human Smallpox.

Volz A, Jany S, Freudenstein A, Lantermann M, Ludwig H, Sutter G.

Viruses. 2018 Jan 4;10(1). pii: E21. doi: 10.3390/v10010021.

18.

Shark island pedicle flap for reconstruction of the lateral nasal ala and perialar defects.

Volz A, Frauenknecht V, Häusermann P.

J Dtsch Dermatol Ges. 2018 Jan;16(1):108-111. doi: 10.1111/ddg.13397. Epub 2017 Dec 12. No abstract available.

PMID:
29232049
19.

Modified Vaccinia Virus Ankara Preferentially Targets Antigen Presenting Cells In Vitro, Ex Vivo and In Vivo.

Altenburg AF, van de Sandt CE, Li BWS, MacLoughlin RJ, Fouchier RAM, van Amerongen G, Volz A, Hendriks RW, de Swart RL, Sutter G, Rimmelzwaan GF, de Vries RD.

Sci Rep. 2017 Aug 17;7(1):8580. doi: 10.1038/s41598-017-08719-y.

20.

A synthetic human cytomegalovirus pp65-IE1 fusion antigen efficiently induces and expands virus specific T cells.

Link EK, Brandmüller C, Suezer Y, Ameres S, Volz A, Moosmann A, Sutter G, Lehmann MH.

Vaccine. 2017 Sep 12;35(38):5131-5139. doi: 10.1016/j.vaccine.2017.08.019. Epub 2017 Aug 14.

PMID:
28818566
21.

Target-Mediated Drug Disposition Pharmacokinetic-Pharmacodynamic Model of Bosentan and Endothelin-1.

Volz AK, Krause A, Haefeli WE, Dingemanse J, Lehr T.

Clin Pharmacokinet. 2017 Dec;56(12):1499-1511. doi: 10.1007/s40262-017-0534-4.

PMID:
28401480
22.

EGF and hydrocortisone as critical factors for the co-culture of adipogenic differentiated ASCs and endothelial cells.

Volz AC, Huber B, Schwandt AM, Kluger PJ.

Differentiation. 2017 May - Jun;95:21-30. doi: 10.1016/j.diff.2017.01.002. Epub 2017 Jan 20.

PMID:
28135608
23.

Modified Vaccinia Virus Ankara: History, Value in Basic Research, and Current Perspectives for Vaccine Development.

Volz A, Sutter G.

Adv Virus Res. 2017;97:187-243. doi: 10.1016/bs.aivir.2016.07.001. Epub 2016 Aug 1. Review.

PMID:
28057259
24.
25.

Increased Protein Degradation Improves Influenza Virus Nucleoprotein-Specific CD8+ T Cell Activation In Vitro but Not in C57BL/6 Mice.

Altenburg AF, van de Sandt CE, van Trierum SE, De Gruyter HLM, van Run PRWA, Fouchier RAM, Roose K, Saelens X, Volz A, Sutter G, de Vries RD, Rimmelzwaan GF.

J Virol. 2016 Oct 28;90(22):10209-10219. doi: 10.1128/JVI.01633-16. Print 2016 Nov 15.

26.

Non-plaque-forming virions of Modified Vaccinia virus Ankara express viral genes.

Lülf AT, Freudenstein A, Marr L, Sutter G, Volz A.

Virology. 2016 Dec;499:322-330. doi: 10.1016/j.virol.2016.09.006. Epub 2016 Oct 11.

27.

Low pathogenic avian influenza (H9N2) in chicken: Evaluation of an ancestral H9-MVA vaccine.

Ducatez MF, Becker J, Freudenstein A, Delverdier M, Delpont M, Sutter G, Guérin JL, Volz A.

Vet Microbiol. 2016 Jun 30;189:59-67. doi: 10.1016/j.vetmic.2016.04.025. Epub 2016 Apr 26.

PMID:
27259828
28.

Tuberculosis control.

del Granado M, López R, Victoria J, Volz A, Tenorio A, Espinal MA.

Lancet. 2016 Mar 19;387(10024):1158. doi: 10.1016/S0140-6736(16)00707-8. No abstract available.

PMID:
27025329
29.

Adipose-derived stem cell differentiation as a basic tool for vascularized adipose tissue engineering.

Volz AC, Huber B, Kluger PJ.

Differentiation. 2016 Jul-Aug;92(1-2):52-64. doi: 10.1016/j.diff.2016.02.003. Epub 2016 Mar 11. Review.

PMID:
26976717
30.

Psychoeducation Improves Compliance and Outcome in Schizophrenia Without an Increase of Adverse Side Effects: A 7-Year Follow-up of the Munich PIP-Study.

Bäuml J, Pitschel-Walz G, Volz A, Lüscher S, Rentrop M, Kissling W, Jahn T.

Schizophr Bull. 2016 Jul;42 Suppl 1:S62-70. doi: 10.1093/schbul/sbw008. Epub 2016 Mar 8.

31.

Immunogenicity and protective efficacy of recombinant Modified Vaccinia virus Ankara candidate vaccines delivering West Nile virus envelope antigens.

Volz A, Lim S, Kaserer M, Lülf A, Marr L, Jany S, Deeg CA, Pijlman GP, Koraka P, Osterhaus AD, Martina BE, Sutter G.

Vaccine. 2016 Apr 7;34(16):1915-26. doi: 10.1016/j.vaccine.2016.02.042. Epub 2016 Mar 2.

PMID:
26939903
32.

Myristoylation increases the CD8+T-cell response to a GFP prototype antigen delivered by modified vaccinia virus Ankara.

Marr L, Lülf AT, Freudenstein A, Sutter G, Volz A.

J Gen Virol. 2016 Apr;97(4):934-40. doi: 10.1099/jgv.0.000425. Epub 2016 Feb 10.

PMID:
26864442
33.

[Modified vaccinia virus ankara (MVA)--development as recombinant vaccine and prospects for use in veterinary medicine].

Volz A, Fux R, Langenmayer MC, Sutter G.

Berl Munch Tierarztl Wochenschr. 2015 Nov-Dec;128(11-12):464-72. Review. German.

PMID:
26697713
34.

An orthopoxvirus-based vaccine reduces virus excretion after MERS-CoV infection in dromedary camels.

Haagmans BL, van den Brand JM, Raj VS, Volz A, Wohlsein P, Smits SL, Schipper D, Bestebroer TM, Okba N, Fux R, Bensaid A, Solanes Foz D, Kuiken T, Baumgärtner W, Segalés J, Sutter G, Osterhaus AD.

Science. 2016 Jan 1;351(6268):77-81. doi: 10.1126/science.aad1283. Epub 2015 Dec 17.

35.

Understanding the effects of mature adipocytes and endothelial cells on fatty acid metabolism and vascular tone in physiological fatty tissue for vascularized adipose tissue engineering.

Huber B, Volz AC, Kluger PJ.

Cell Tissue Res. 2015 Nov;362(2):269-79. doi: 10.1007/s00441-015-2274-9. Epub 2015 Sep 4. Review.

PMID:
26340984
36.

How do culture media influence in vitro perivascular cell behavior?

Huber B, Volz AC, Kluger PJ.

Cell Biol Int. 2015 Dec;39(12):1395-407. doi: 10.1002/cbin.10515. Epub 2015 Aug 6.

PMID:
26179857
37.

Protective Efficacy of Recombinant Modified Vaccinia Virus Ankara Delivering Middle East Respiratory Syndrome Coronavirus Spike Glycoprotein.

Volz A, Kupke A, Song F, Jany S, Fux R, Shams-Eldin H, Schmidt J, Becker C, Eickmann M, Becker S, Sutter G.

J Virol. 2015 Aug;89(16):8651-6. doi: 10.1128/JVI.00614-15. Epub 2015 May 27.

38.

How accurate is the treatment of midfacial fractures by a specific navigation system integrating "mirroring" computational planning? Beyond mere average difference analysis.

Pierrefeu A, Terzic A, Volz A, Courvoisier D, Scolozzi P.

J Oral Maxillofac Surg. 2015 Feb;73(2):315.e1-315.e10. doi: 10.1016/j.joms.2014.09.022. Epub 2014 Oct 13.

PMID:
25579017
39.

Safety and immunogenicity of a modified-vaccinia-virus-Ankara-based influenza A H5N1 vaccine: a randomised, double-blind phase 1/2a clinical trial.

Kreijtz JH, Goeijenbier M, Moesker FM, van den Dries L, Goeijenbier S, De Gruyter HL, Lehmann MH, Mutsert Gd, van de Vijver DA, Volz A, Fouchier RA, van Gorp EC, Rimmelzwaan GF, Sutter G, Osterhaus AD.

Lancet Infect Dis. 2014 Dec;14(12):1196-207. doi: 10.1016/S1473-3099(14)70963-6. Epub 2014 Oct 30.

PMID:
25455987
40.

Potent cholesteryl ester transfer protein inhibitors of reduced lipophilicity: 1,1'-spiro-substituted hexahydrofuroquinoline derivatives.

Trieselmann T, Wagner H, Fuchs K, Hamprecht D, Berta D, Cremonesi P, Streicher R, Luippold G, Volz A, Markert M, Nar H.

J Med Chem. 2014 Nov 13;57(21):8766-76. doi: 10.1021/jm500431d. Epub 2014 Oct 27.

PMID:
25265559
41.

Recombinant modified vaccinia virus Ankara expressing glycoprotein E2 of Chikungunya virus protects AG129 mice against lethal challenge.

van den Doel P, Volz A, Roose JM, Sewbalaksing VD, Pijlman GP, van Middelkoop I, Duiverman V, van de Wetering E, Sutter G, Osterhaus AD, Martina BE.

PLoS Negl Trop Dis. 2014 Sep 4;8(9):e3101. doi: 10.1371/journal.pntd.0003101. eCollection 2014 Sep.

42.

Modified vaccinia virus ankara (MVA) as production platform for vaccines against influenza and other viral respiratory diseases.

Altenburg AF, Kreijtz JH, de Vries RD, Song F, Fux R, Rimmelzwaan GF, Sutter G, Volz A.

Viruses. 2014 Jul 17;6(7):2735-61. doi: 10.3390/v6072735. Review.

43.
44.

The role of daily hassles and distress tolerance in predicting cigarette craving during a quit attempt.

Volz AR, Dennis PA, Dennis MF, Calhoun PS, Wilson SM, Beckham JC.

Nicotine Tob Res. 2014 Jun;16(6):872-5. doi: 10.1093/ntr/ntt286. Epub 2014 Jan 28.

45.

Impact of endogenous esterase activity on in vitro p-glycoprotein profiling of dabigatran etexilate in Caco-2 monolayers.

Ishiguro N, Kishimoto W, Volz A, Ludwig-Schwellinger E, Ebner T, Schaefer O.

Drug Metab Dispos. 2014 Feb;42(2):250-6. doi: 10.1124/dmd.113.053561. Epub 2013 Nov 8.

PMID:
24212377
46.

Practical aspects of recruitment and retention in clinical trials of rare genetic diseases: the phenylketonuria (PKU) experience.

DeWard SJ, Wilson A, Bausell H, Volz AS, Mooney K.

J Genet Couns. 2014 Feb;23(1):20-8. doi: 10.1007/s10897-013-9642-y. Epub 2013 Sep 8.

PMID:
24014152
47.

Middle East respiratory syndrome coronavirus spike protein delivered by modified vaccinia virus Ankara efficiently induces virus-neutralizing antibodies.

Song F, Fux R, Provacia LB, Volz A, Eickmann M, Becker S, Osterhaus AD, Haagmans BL, Sutter G.

J Virol. 2013 Nov;87(21):11950-4. doi: 10.1128/JVI.01672-13. Epub 2013 Aug 28.

48.

Protective efficacy of Modified Vaccinia virus Ankara in preclinical studies.

Volz A, Sutter G.

Vaccine. 2013 Sep 6;31(39):4235-40. doi: 10.1016/j.vaccine.2013.03.016. Epub 2013 Mar 21. Review.

PMID:
23523402
49.

CathAway fistula vascular access program achieves improved outcomes and sets a new standard of treatment for end-stage renal disease.

Wilson SM, Mayne TJ, Krishnan M, Holland J, Volz A, Good LS, Nissenson AR.

Hemodial Int. 2013 Jan;17(1):86-93. doi: 10.1111/j.1542-4758.2012.00721.x. Epub 2012 Jun 29.

PMID:
22742528
50.

Easy and efficient protocols for working with recombinant vaccinia virus MVA.

Kremer M, Volz A, Kreijtz JH, Fux R, Lehmann MH, Sutter G.

Methods Mol Biol. 2012;890:59-92. doi: 10.1007/978-1-61779-876-4_4.

PMID:
22688761

Supplemental Content

Support Center